X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sterling Biotech with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs ASTRAZENECA PHARMA - Comparison Results

STERLING BIOTECH    Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH ASTRAZENECA PHARMA STERLING BIOTECH/
ASTRAZENECA PHARMA
 
P/E (TTM) x -0.4 117.5 - View Chart
P/BV x 0.0 22.8 0.1% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 STERLING BIOTECH   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
ASTRAZENECA PHARMA
Mar-18
STERLING BIOTECH/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs111,278 0.8%   
Low Rs3883 0.4%   
Sales per share (Unadj.) Rs26.8228.4 11.7%  
Earnings per share (Unadj.) Rs-15.010.4 -144.3%  
Cash flow per share (Unadj.) Rs-5.516.3 -33.6%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs54.998.8 55.6%  
Shares outstanding (eoy) m267.8725.00 1,071.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.34.7 5.5%   
Avg P/E ratio x-0.5104.2 -0.4%  
P/CF ratio (eoy) x-1.366.4 -1.9%  
Price / Book Value ratio x0.110.9 1.2%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,86227,008 6.9%   
No. of employees `0001.41.4 99.9%   
Total wages/salary Rs m5471,535 35.6%   
Avg. sales/employee Rs Th5,303.34,210.9 125.9%   
Avg. wages/employee Rs Th403.81,132.2 35.7%   
Avg. net profit/employee Rs Th-2,959.0191.1 -1,548.6%   
INCOME DATA
Net Sales Rs m7,1815,710 125.8%  
Other income Rs m43123 34.8%   
Total revenues Rs m7,2235,833 123.8%   
Gross profit Rs m947463 204.6%  
Depreciation Rs m2,543147 1,725.4%   
Interest Rs m4,3770-   
Profit before tax Rs m-5,931438 -1,354.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1,924179 -1,075.6%   
Profit after tax Rs m-4,007259 -1,546.3%  
Gross profit margin %13.28.1 162.7%  
Effective tax rate %32.440.8 79.4%   
Net profit margin %-55.84.5 -1,229.6%  
BALANCE SHEET DATA
Current assets Rs m14,3353,209 446.7%   
Current liabilities Rs m49,8092,070 2,406.8%   
Net working cap to sales %-494.020.0 -2,475.1%  
Current ratio x0.31.6 18.6%  
Inventory Days Days40372 557.7%  
Debtors Days Days17135 488.7%  
Net fixed assets Rs m55,432790 7,014.1%   
Share capital Rs m26850 535.8%   
"Free" reserves Rs m13,9352,419 576.0%   
Net worth Rs m14,7012,469 595.4%   
Long term debt Rs m9,4780-   
Total assets Rs m73,9884,605 1,606.6%  
Interest coverage x-0.4NM-  
Debt to equity ratio x0.60-  
Sales to assets ratio x0.11.2 7.8%   
Return on assets %0.55.6 8.9%  
Return on equity %-27.310.5 -259.7%  
Return on capital %-6.417.7 -36.2%  
Exports to sales %25.90-   
Imports to sales %0.20-   
Exports (fob) Rs m1,860NA-   
Imports (cif) Rs m12NA-   
Fx inflow Rs m1,860300 620.9%   
Fx outflow Rs m252,015 1.2%   
Net fx Rs m1,835-1,715 -107.0%   
CASH FLOW
From Operations Rs m1,71988 1,955.3%  
From Investments Rs m-3,148-94 3,363.5%  
From Financial Activity Rs m1,426NA-  
Net Cashflow Rs m-3-6 59.6%  

Share Holding

Indian Promoters % 33.9 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 0.0 0.3 -  
FIIs % 9.9 15.7 63.1%  
ADR/GDR % 16.9 0.0 -  
Free float % 39.3 9.1 431.9%  
Shareholders   21,482 12,856 167.1%  
Pledged promoter(s) holding % 55.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   PFIZER  ABBOTT INDIA  PLETHICO PHARMA  DR. REDDYS LAB  GSK PHARMA  

Compare STERLING BIOTECH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tanks 495 Points, Jet Airways in Focus and Other Top Stocks in Action Today(Pre-Open)

On Monday, share markets in India opened on a negative note and ended the day deep in red after a volatile day of trading.

Related Views on News

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 66.7% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 91 m (down 66.7% YoY). Sales on the other hand came in at Rs 2 bn (down 1.8% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 10.3% (Quarterly Result Update)

Aug 21, 2018 | Updated on Aug 21, 2018

For the quarter ended June 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 64 m (up 10.3% YoY). Sales on the other hand came in at Rs 2 bn (up 25.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 212.1% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 32 m (down 212.1% YoY). Sales on the other hand came in at Rs 2 bn (up 35.1% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

3 Indian Stocks with Amazon-Like Potential(Profit Hunter)

Apr 10, 2019

We have identified 3 stocks with huge wealth building potential which meet our 'Click of a Button' criteria.

This Company is Making a Big Comeback and You Can Now Profit from Its Example(The 5 Minute Wrapup)

Apr 10, 2019

How Dell got its mojo back.

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)

Apr 12, 2019

Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.

A Simple 3-Point Investing Manifesto for You the Indian Investor(The 5 Minute Wrapup)

Apr 11, 2019

A must have checklist for every investor in the Indian stock market.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Nov 5, 2018 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH 5-YR ANALYSIS

COMPARE STERLING BIOTECH WITH

MARKET STATS